Novo Nordisk's Strategic Pivot: Exploring New Avenues Beyond GLP-1 Dominance

Novo Nordisk starts Phase 1 trial for oral drug LX9851, a novel obesity treatment targeting fat metabolism, separate from its GLP-1 drugs like semaglutide.

Novo Nordisk is advancing a novel research pathway in obesity treatment, signaling a strategic expansion beyond its blockbuster GLP-1-based therapies. The Danish pharmaceutical giant, in collaboration with Lexicon Pharmaceuticals, has initiated a Phase 1 clinical trial for an investigational oral drug candidate known as LX9851. This compound represents a distinct biological approach, operating through a mechanism entirely separate from the incretin pathway that underpins drugs like semaglutide.

A Distinct Therapeutic Pathway

The candidate drug LX9851 functions by selectively inhibiting the enzyme Acyl-CoA Synthetase 5 (ACSL5), a key player in fat metabolism and energy regulation within the body. This fundamental difference in action separates it from the current class of GLP-1 receptor agonists. Novo Nordisk secured an exclusive global license for the development and commercialization of this asset.

The newly launched study will assess the safety, tolerability, and pharmacological profile of LX9851 in a cohort of 96 individuals living with overweight or obesity. Completion of this initial phase is scheduled for the first quarter of 2027.

Early preclinical data, unveiled at the Obesity Week 2024 conference, offer a glimpse into the compound's potential. When combined with semaglutid, LX9851 demonstrated a greater reduction in body weight compared to semaglutid administered alone. Furthermore, the treatment appeared to mitigate weight regain following the discontinuation of semaglutid and showed positive effects on liver fat. These findings suggest LX9851 could eventually be positioned not as a replacement for existing GLP-1 therapies, but as a complementary treatment option.

Navigating Core Business Headwinds

The timing of this clinical milestone is strategic. Novo Nordisk faces mounting pressure on its core business. The company has projected a revenue decline of five to thirteen percent for 2026 on a constant currency basis, primarily attributed to unprecedented pricing concessions within its flagship GLP-1 segment.

For its partner Lexicon Pharmaceuticals, the trial initiation triggers a second milestone payment this year, worth ten million US dollars. The agreement holds the potential for Lexicon to receive up to one billion dollars in total from future milestone achievements and royalty streams.

A note for shareholders: The ex-dividend date for a payout of 7.95 Danish kroner per share is set for March 27, 2026, with payment following on March 31. Novo Nordisk's share price is currently trading near its 52-week low, having declined approximately 29 percent since the start of the year. This performance reflects persistent market uncertainty surrounding the company's primary revenue drivers.